A
194.27
0.37 (0.19%)
| Previous Close | 193.90 |
| Open | 194.59 |
| Volume | 345,184 |
| Avg. Volume (3M) | 476,836 |
| Market Cap | 11,763,903,488 |
| Price / Sales | 19.68 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -92.67% |
| Operating Margin (TTM) | -103.23% |
| Diluted EPS (TTM) | -6.79 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | -218.93 M |
| Levered Free Cash Flow (TTM) | -133.44 M |
| Return on Assets (TTM) | -22.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ascendis Pharma A/S | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 113.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 307.00 (UBS, 58.03%) | Buy |
| Median | 250.00 (28.69%) | |
| Low | 203.00 (Cantor Fitzgerald, 4.49%) | Buy |
| Average | 249.91 (28.64%) | |
| Total | 11 Buy | |
| Avg. Price @ Call | 186.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 19 Aug 2025 | 260.00 (33.83%) | Buy | 194.62 |
| 29 Jul 2025 | 254.00 (30.75%) | Buy | 163.32 | |
| Cantor Fitzgerald | 08 Aug 2025 | 203.00 (4.49%) | Buy | 191.49 |
| Citigroup | 08 Aug 2025 | 290.00 (49.28%) | Buy | 191.49 |
| 11 Jul 2025 | 243.00 (25.08%) | Buy | 174.96 | |
| RBC Capital | 08 Aug 2025 | 230.00 (18.39%) | Buy | 191.49 |
| Stifel | 08 Aug 2025 | 254.00 (30.75%) | Buy | 191.49 |
| UBS | 08 Aug 2025 | 307.00 (58.03%) | Buy | 191.49 |
| Wedbush | 08 Aug 2025 | 220.00 (13.24%) | Buy | 191.49 |
| Wells Fargo | 08 Aug 2025 | 295.00 (51.85%) | Buy | 191.49 |
| Morgan Stanley | 03 Jul 2025 | 250.00 (28.69%) | Buy | 174.18 |
| Oppenheimer | 13 Jun 2025 | 224.00 (15.30%) | Buy | 170.80 |
| B of A Securities | 09 Jun 2025 | 216.00 (11.19%) | Buy | 173.15 |
| 03 Jun 2025 | 201.00 (3.46%) | Buy | 174.40 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference |
| 07 Aug 2025 | Announcement | Ascendis Pharma Reports Second Quarter 2025 Financial Results |
| 31 Jul 2025 | Announcement | Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 |
| 28 Jul 2025 | Announcement | FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency |
| 14 Jul 2025 | Announcement | New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life |
| 07 Jul 2025 | Announcement | Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 |
| 09 Jun 2025 | Announcement | TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |